Ascendis Pharma Files 6-K for S-8 Registration
Ticker: ASND · Form: 6-K · Filed: Oct 22, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, registration, form-6k
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, likely related to stock registration. Keep an eye on share count.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on October 22, 2025, to report information as a foreign private issuer. The filing is related to their registration statements on Form S-8, specifically referencing registration numbers 333-203040 and 333-21. The company is incorporated in G7 and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing or updated registration of securities, potentially related to employee stock plans or other equity issuances, which can impact share count and investor dilution.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to existing registration statements and does not appear to contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-21 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is filed by Ascendis Pharma A/S as a report of a foreign private issuer and is incorporated by reference into their registration statements on Form S-8.
What are the relevant registration numbers mentioned in the filing?
The filing references registration statements on Form S-8 with Registration Numbers 333-203040 and 333-21.
When was this Form 6-K filed?
This Form 6-K was filed on October 22, 2025.
Where is Ascendis Pharma A/S located?
Ascendis Pharma A/S is located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
What is the SEC file number for Ascendis Pharma A/S?
The SEC file number for Ascendis Pharma A/S is 001-36815.
Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 20 · Accepted 2025-10-22 17:00:07
Filing Documents
- d68419d6k.htm (6-K) — 10KB
- 0001193125-25-246974.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: October 22, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer